Eli Lilly and Company (LLY)
NYSE: LLY · Real-Time Price · USD
971.90
+37.30 (3.99%)
May 1, 2026, 10:43 AM EDT - Market open
Revenue
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Quarter | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Sep '25 Sep 30, 2025 | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Sep '23 Sep 30, 2023 | Jun '23 Jun 30, 2023 | Mar '23 Mar 31, 2023 | Dec '22 Dec 31, 2022 | Sep '22 Sep 30, 2022 | Jun '22 Jun 30, 2022 | Mar '22 Mar 31, 2022 | Dec '21 Dec 31, 2021 | Sep '21 Sep 30, 2021 | Jun '21 Jun 30, 2021 | Mar '21 Mar 31, 2021 | Dec '20 Dec 31, 2020 | Sep '20 Sep 30, 2020 | Jun '20 Jun 30, 2020 |
Basaglar Revenue | 206.00M | |||||||||||||||||||||||
Basaglar Revenue Growth | 18.66% | |||||||||||||||||||||||
Humalog Revenue | 442.00M | |||||||||||||||||||||||
Humalog Revenue Growth | -17.72% | |||||||||||||||||||||||
Humulin Revenue | 160.00M | |||||||||||||||||||||||
Humulin Revenue Growth | -7.62% | |||||||||||||||||||||||
Jardiance Revenue | 1.11B | |||||||||||||||||||||||
Jardiance Revenue Growth | 9.82% | |||||||||||||||||||||||
Mounjaro Revenue | 8.66B | |||||||||||||||||||||||
Mounjaro Revenue Growth | 125.47% | |||||||||||||||||||||||
Trajenta Revenue | 76.00M | |||||||||||||||||||||||
Trajenta Revenue Growth | -0.39% | |||||||||||||||||||||||
Trulicity Revenue | 919.00M | |||||||||||||||||||||||
Trulicity Revenue Growth | -16.09% | |||||||||||||||||||||||
Zepbound Revenue | 4.16B | |||||||||||||||||||||||
Zepbound Revenue Growth | 79.94% | |||||||||||||||||||||||
Other Cardiometabolic Health Revenue | 22.00M | |||||||||||||||||||||||
Cardiometabolic Health Revenue | 15.76B | |||||||||||||||||||||||
Cardiometabolic Health Revenue Growth | 71.15% | |||||||||||||||||||||||
Oncology Revenue | 2.27B | |||||||||||||||||||||||
Oncology Revenue Growth | 16.46% | |||||||||||||||||||||||
Immunology Revenue | 1.20B | |||||||||||||||||||||||
Immunology Revenue Growth | 10.57% | |||||||||||||||||||||||
Neuroscience Revenue | 382.00M | |||||||||||||||||||||||
Neuroscience Revenue Growth | 40.39% | |||||||||||||||||||||||
Other Product Revenue | 187.00M | |||||||||||||||||||||||
Other Product Revenue Growth | -12.16% | |||||||||||||||||||||||
Revenue (Other) | -1.00M | |||||||||||||||||||||||
Revenue (Total) | 19.80B | |||||||||||||||||||||||
Revenue (Total) Growth | 55.54% |
Revenue by Geography
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Quarter | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Sep '25 Sep 30, 2025 | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Sep '23 Sep 30, 2023 | Jun '23 Jun 30, 2023 | Mar '23 Mar 31, 2023 | Dec '22 Dec 31, 2022 | Sep '22 Sep 30, 2022 | Jun '22 Jun 30, 2022 | Mar '22 Mar 31, 2022 | Dec '21 Dec 31, 2021 | Sep '21 Sep 30, 2021 | Jun '21 Jun 30, 2021 | Mar '21 Mar 31, 2021 | Dec '20 Dec 31, 2020 | Sep '20 Sep 30, 2020 | Jun '20 Jun 30, 2020 |
US Revenue | 12.12B | |||||||||||||||||||||||
US Revenue Growth | 42.75% | |||||||||||||||||||||||
Europe Revenue | 3.65B | |||||||||||||||||||||||
Europe Revenue Growth | 52.63% | |||||||||||||||||||||||
Japan Revenue | 571.00M | |||||||||||||||||||||||
Japan Revenue Growth | 41.97% | |||||||||||||||||||||||
China Revenue | 693.00M | |||||||||||||||||||||||
China Revenue Growth | 53.73% | |||||||||||||||||||||||
Other Foreign Countries Revenue | 2.77B | |||||||||||||||||||||||
Other Foreign Countries Revenue Growth | 177.82% | |||||||||||||||||||||||
Revenue (Other) | -1.00M | |||||||||||||||||||||||
Revenue (Total) | 19.80B | |||||||||||||||||||||||
Revenue (Total) Growth | 55.54% |
Key Performance Indicators
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Quarter | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Sep '25 Sep 30, 2025 | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Sep '23 Sep 30, 2023 | Jun '23 Jun 30, 2023 | Mar '23 Mar 31, 2023 | Dec '22 Dec 31, 2022 | Sep '22 Sep 30, 2022 | Jun '22 Jun 30, 2022 | Mar '22 Mar 31, 2022 | Dec '21 Dec 31, 2021 | Sep '21 Sep 30, 2021 | Jun '21 Jun 30, 2021 | Mar '21 Mar 31, 2021 | Dec '20 Dec 31, 2020 | Sep '20 Sep 30, 2020 | Jun '20 Jun 30, 2020 |
Revenue Change due to Price | -13.00% | |||||||||||||||||||||||
Revenue Change due to Volume | 65.00% | |||||||||||||||||||||||
Revenue Change due to FX | 4.00% |
Updated Apr 30, 2026. Data Source: Fiscal.ai.